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1) Infectious Diseases Department, 2) Microbiology Department and 3) Renal Transplant Unit, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, SpainAbstractUrinary tract infections (UTIs) are frequent after renal transplantation, but their impact on short-term graft outcome is not well established.
All kidney transplants performed between July 2003 and December 2010 were investigated to evaluate the impact of UTI on graft function at
1 year after transplantation. Of 867 patients who received a kidney transplant, 184 (21%) developed at least one episode of UTI, at a median
of 18 days after transplantation. The prevalence of acute graft pyelonephritis (AGP) was 15%. The most frequent pathogens identiﬁed were
Escherichia coli, Klebsiella species, and Pseudomonas aeruginosa, 37% of which were considered to be multidrug-resistant strains. Thirty-eight
patients (4%) lost their grafts, 225 patients (26%) had graft function impairment and the 1-year mortality rate was 3%; however, no patient
died as a consequence of a UTI. Surgical re-intervention and the development of at least one episode of AGP were independently associated
with 1-year graft function impairment. Moreover, the development of at least one episode of AGP was associated with graft loss at 1 year.
Patients with AGP caused by a resistant strain had graft function impairment more frequently, although this difference did not reach statistical
signiﬁcance (53% vs. 36%, p 0.07). Neither asymptomatic bacteriuria nor acute uncomplicated UTI were associated with graft function
impairment in multivariate analysis. To conclude, UTIs are frequent in kidney transplant recipients, especially in the early post-
transplantation period. Although AGP was signiﬁcantly associated with kidney graft function impairment and 1-year post-transplantation
graft loss, lower UTIs did not affect graft function.
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ub.es (C. Cervera)IntroductionUrinary tract infection (UTI) is the most common infectious
complication in solid organ transplant recipients, accounting for
45–72% for all infections [1,2]. Its incidence and clinical pre-
sentation differ according to the type of organ transplanted. The
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nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.07.019(RESITRA) reported incidence rates of cystitis and pyelonephritis
of 13.84 and 3.66 episodes per 100 recipient-years, respectively,
among kidney transplant patients, with the highest incidence in
the ﬁrst 3–6 months after transplantation [3].
The high rate of bacterial invasion among transplant re-
cipients could be explained by different mechanisms, including
the speciﬁc surgical and immunological trauma, the inﬂuence of
early intense immunosuppression, and the requirement for
urinary catheterization after the surgical procedure. Although
early removal of urethral catheters, improved surgical tech-
niques and appropriate perioperative antibiotic prophylaxis
regimens have reduced the incidence of UTI, it remains higher
than in the general population [4,5].
It is unclear whether the development of a UTI has an impact
on kidney graft function. Some studies have demonstrated anious Diseases. Published by Elsevier Ltd. All rights reserved
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ney graft function impairment, and even with graft survival
[2,6,7], whereas others could ﬁnd no such association [8].
Another relevant and unresolved issue is whether recurrent
lower-tract UTI, which is highly prevalent in this clinical setting,
affects the long-term function of kidney grafts. However, there
is very little information on the inﬂuence of asymptomatic
bacteriuria (AB) or non-febrile UTIs on the long-term out-
comes of kidney transplant recipients.
In this study, we aimed to analyse the clinical impact of UTIs
on graft function and 1-year post-transplantation graft survival
in kidney transplant recipients.Materials and methodsSetting and study population
We conducted a retrospective observational study at a ter-
tiary university referral hospital in Barcelona, Spain. This
hospital has an active kidney transplantation programme,
performing an annual average of 120 procedures. We pro-
spectively recorded baseline data of all consecutive kidney
transplants performed between 1 July 2003 and 31 December
2010, using a purpose-designed database. We included the
following data: immunosuppressive treatment, the occurrence
of acute allograft rejection (only biopsy-proven acute allograft
rejection), the occurrence of opportunistic infections, and the
clinical features, microbiological ﬁndings and outcomes of any
UTI. The study was approved by our institution’s Ethics
Committee.
Clinical data and deﬁnitions
UTI was diagnosed according to the guidelines of the Infectious
Diseases Society of America and the European Society of
Clinical Microbiology and Infectious Diseases [9,10]. UTI was
considered only in symptomatic episodes occurring in the ﬁrst
year after transplantation. For AB, we used modiﬁed criteria
deﬁned as a urine culture yielding signiﬁcant growth of urinary
tract pathogens (105 CFU/mL) in the absence of symptoms
attributable to infection. Patients with dysuria, urinary fre-
quency/urgency, suprapubic pain without fever and a positive
urine culture (104 CFU/mL) were categorized as having acute
uncomplicated (AU) UTI, which included cystitis and prostatitis.
Patients with fever (with or without ﬂank/allograft pain) and a
urine culture positive for urinary tract pathogens (104 CFU/
mL) were diagnosed as having AGP. Recurrent UTI was deﬁned
as the occurrence of at least three episodes of symptomatic
UTI in a 12-month period or two episodes within 6 months
with positive cultures, as previously described [11,12]. Re-
operation represented an operation on any portion of theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeurinary tract, excluding a new transplant. Nephrostomy, cyto-
megalovirus (CMV) infection and fungal infection were
considered if they occurred prior to the ﬁrst UTI episode. CMV
infection was considered as described elsewhere [13]. Urine
cultures were systematically performed when the urethral
catheter was removed and when infection-attributable symp-
toms occurred. The urethral catheter was placed at the time of
transplantation. The planned time to stent removal was 7–10
days after transplantation. Inadequate empirical antibiotic
treatment was considered if the treatment regimen did not
include at least one antibiotic active in vitro against the infecting
microorganism.
UTI treatment protocol
According to our guidelines for the management of infection
after kidney transplantation, patients with cystitis were treated
for 5–7 days, and patients with prostatitis or AGP were treated
for 14–21 days. Although there is no consensus on whether AB
should be treated in renal transplant recipients, the ﬁnal deci-
sion was taken at the discretion of the attending physician.
Impairment of renal function
We deﬁned impaired kidney graft function according to the
Risk, Injury, Failure, Loss, and End-stage kidney disease criteria
[14,15]. Serum creatinine increases of 1.5–2-fold, or decreases
in the glomerular ﬁltration rate of >25% over baseline, were
also considered in the deﬁnition of impaired kidney graft
function. Baseline serum creatinine and glomerular ﬁltration
rate were registered 30 days after the transplant procedure.
Graft loss was deﬁned as a deﬁnitive requirement for
haemodialysis.
Multidrug resistance
In accordance with standard deﬁnitions, a pathogen was
deﬁned as multidrug-resistant (MDR) when it lacked suscepti-
bility to one or more agents in three or more antimicrobial
categories [16].
Prophylaxis protocol
Kidney recipients received perioperative antibacterial prophy-
laxis with a single dose of cefazolin. During the study period,
prophylaxis against Pneumocystis jiroveci infection was performed
with daily trimethoprim–sulphamethoxazole 80/400 mg during
the ﬁrst 6 months after transplantation. CMV-seronegative
recipients of CMV-seropositive donor grafts received prophy-
laxis with either intravenous ganciclovir or oral valganciclovir
for 3 months. CMV-seropositive recipients followed a pre-
emptive strategy according to published guidelines [17]. Pa-
tients requiring induction therapy with antithymocyte globulins
received valganciclovir for 1 month.ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1104.e1–1104.e8
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Urine samples were inoculated onto a cystine lactose
electrolyte-deﬁcient medium agar plate with a 1-μL calibrated
loop for quantitative culture, and incubated at 36°C for 48 h.
Microorganism identiﬁcation and susceptibility testing were
performed with commercial panels from the MicroScan auto-
mated system (Siemens Healthcare Diagnostics, West Sacra-
mento, CA, USA) for the 2003–2004 period, and the Phoenix
automated system (Becton Dickinson, Sparks, MD, USA) for
2005–2010. CLSI criteria were used to deﬁne susceptibility or
resistance to antimicrobial agents [18]. In accordance with CLSI
guidelines, we tested for extended spectrum β-lactamase
(ESBL) production with a double-disk synergy test, for carba-
penemase production in carbapenem-resistant strains with a
modiﬁed Hodge method, and for metallo-β-lactamase with a
double-disk synergy test with EDTA disks [18].
Statistical analysis
In the comparative analyses, we used the chi-square test with
Yate’s correction for categorical variables. Continuous variables
were compared by use of the t-test or Mann–Whitney U-test,
depending on their homogeneity. Statistically signiﬁcant vari-
ables in the univariate analysis were entered into a multivariate
model for logistic regression analysis, and the ORs and 95% CIs
were calculated. Age and gender were included in the ﬁnal
regression model due to theoretical reasons. The analysis was
performed with the stepwise logistic regression model of
PASW Statistics for Windows, Version 18.0 (SPSS, Chicago,867 consecutive 
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threshold of statistical signiﬁcance was set at p <0.05.ResultsWe included 867 adult patients who underwent kidney trans-
plantation during the 7-year study period, and who had a me-
dian follow-up of 542 days (range, 14–3004 days). During the
ﬁrst year post-transplantation, 455 patients did not develop a
UTI (52%), 228 (26%) developed AB, 58 (7%) developed AU
UTI, and 126 (15%) developed AGP. Of those with a UTI, 55
developed recurrent UTI (6%). The median time from trans-
plantation to the ﬁrst episode of UTI was 18 days (range, 0–620
days). Fig. 1 shows the patient ﬂow during the study.
Table 1 shows the baseline, demographic and clinical char-
acteristics by type (or absence) of UTI. CMV and invasive fungal
infection, surgical re-intervention, nephrostomy and need for
post-transplantion haemodialysis were more frequent among
patients with AGP. Sixty per cent of patients with AGP had
positive blood cultures. Patients who received an organ from a
deceased donor had UTI more frequently, especially AGP. In
addition, 38 patients (4%) lost their kidney graft and 225 (26%)
had kidney graft function impairment. The median duration of
urethral catheterization after transplantation was 8 days
(interquartile range, 7–15 days), without statistically signiﬁcant
differences between patients with AU UTI and AGP and those
with without UTI or with AB. Patients with AGP had worseUTI
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TABLE 1. Univariate analysis of baseline, demographic and clinical characteristics and outcomes depending on the presence of
urinary tract infection (UTI)
Non-UTI (n [ 455) AB (n [ 228) AU UTI (n [ 58) AGP (n [ 126) p
Female sex, n (%) 166 (37) 109 (48) 24 (41) 48 (38) 0.7
Age (years), median (range) 49 (16–81) 50 (18–78) 59 (19–73) 55 (18–75) 0.2
Prior transplantation, n (%) 132 (29) 62 (27) 12 (21) 32 (25) 0.5
Diabetes mellitus, n (%) 60 (13) 25 (11) 11 (19) 17 (14) 0.4
Heart disease, n (%) 94 (21) 48 (21) 12 (21) 32 (25) 0.7
CMV D+/R–a, n (%) 47 (10) 21 (9) 12 (21) 13 (10) 0.07
HCV, n (%) 62 (14) 31 (14) 8 (14) 19 (15) 0.9
HIV, n (%) 6 (1) 3 (1) 0 1 (1) 0.8
Type of donor, n (%)
Living 116 (25) 65 (28) 12 (21) 12 (9) 0.002
Deceased 339 (75) 163 (72) 46 (79) 114 (91) 0.03
Donor age (years), median (range) 52 (9–83) 52 (17–80) 56 (17–79) 56 (23–83) 0.9
Induction therapy, n (%) 362 (80) 192 (84) 43 (74) 105 (83) 0.2
Basiliximab 173 (38) 93 (43) 27 (47) 47 (37) 0.8
Thymoglobulin 172 (38) 89 (38) 16 (27) 52 (42) 0.4
CMV infection, n (%) 41 (9) 25 (11) 8 (14) 22 (18) 0.05
Invasive fungal infection, n (%) 10 (2) 10 (4) 3 (5) 12 (10) 0.003
BK virus infection, n (%) 9 (2) 4 (2) 1 (2) 0 0.5
Re-intervention, n (%) 120 (26) 64 (28) 21 (36) 51 (41) 0.01
Diagnosis of any malignancy in the ﬁrst year after transplantation, n (%) 4 (1) 4 (2) 1 (2) 1 (1) 0.7
Nephrostomy, n (%) 19 (4) 9 (4) 4 (7) 22 (18) <0.001
Duration (days) of urethral catheterization, median (range) 8 (0–72) 8 (0–375) 9 (6–67) 9 (4–82) 0.2
Vesiculoureteric reﬂux, n (%) 25 (6) 13 (6) 4 (7) 4 (3) 0.6
Haemodialysis post-transplantation, n (%) 105 (23) 58 (25) 17 (29) 62 (49) <0.001
Requirement for ureteral pigtail catheter, n (%) 3 (1) 2 (1) 3 (6) 12 (11) <0.001
Acute allograft rejection, n (%) 93 (20) 50 (22) 17 (29) 39 (31) 0.06
Thymoglobulin 4 (21) 2 (15) 2 (40) 1 (20) 0.8
Receipt of more than one pulse of 0.5 g of intravenous
methylprednisolone
13 (65) 3 (23) 3 (50) 3 (50) 0.1
Rituximab 4 (20) 2 (15) 2 (40) 4 (57) 0.1
Impaired kidney graft function, n (%) 105 (26) 59 (27) 14 (27) 47 (43) 0.004
Serum creatinine level (mg/dl) at 1 month post-transplantation, median (range) 1.53 (0.5–16) 1.45 (0.7–11) 1.7 (1–8) 2 (1–13) <0.001
Glomerular ﬁltration rate (ml/min/m2) at 1 month post-transplantation, median
(range)
51 (1–140) 55 (1–126) 51 (4–119) 33 (1–116) <0.001
Serum creatinine level (mg/dl) at 1 year post-transplantation, median (range) 1.4 (0.7–11) 1.3 (0.7–8) 1.5 (0.9–7) 1.7 (0.8–8.5) <0.001
Glomerular ﬁltration rate (ml/min/m2) at 1 year post-transplantation, median
(range)
58 (6–148) 60 (3–141) 56 (10–120) 51 (7–129) <0.001
Graft loss, n (%) 18 (4) 3 (1) 3 (5) 14 (11) <0.001
One-year mortality, n (%) 15 (3) 3 (1) 1 (2) 7 (6) 0.4
AB, asymptomatic bacteriuria; AGP, acute graft pyelonephritis; AU, acute uncomplicated; CMV, cytomegalovirus; HCV, hepatitis C virus; HIV, human immunodeﬁciency virus.
aD+/R– : CMV-seronegative recipients of grafts from CMV-seropositive donors.
FIG. 2. Microbiology study of urinary tract infection episodes by
antimicrobial susceptibility. Escherichia coli and Klebsiella species strains
were classiﬁed according to the presence or absence of extended-
spectrum β-lactamase-production. Pseudomonas aeruginosa strains
were classiﬁed according to multidrug resistance, and Enterococcus
species strains were classiﬁed according to vancomycin susceptibility.
CMI Bodro et al. Impact of acute pyelonephritis on graft survival 1104.e4outcomes in terms of impaired kidney graft function and graft
loss. The 1-year mortality rate was 3%, but no patient died as a
consequence of a UTI.
Sixty per cent of patients with AGP had positive blood cul-
tures. Inadequate empirical antibiotic treatment was prescribed
in 20% of AGP episodes.
The most frequent pathogen identiﬁed was Escherichia coli,
followed by Klebsiella species, Pseudomonas aeruginosa, and
Enterococcus species. The antimicrobial susceptibilities of the
isolates are shown in Fig. 2. ESBL-producing Klebsiella species
accounted for 74% of all Klebsiella species isolates, ESBL-
producing E. coli for 25%, and MDR P. aeruginosa for 38%.
We found no episodes of infection with vancomycin-resistant
Enterococcus faecium. Resistant strains (ESBL-producing Enter-
obacteriaceae and MDR P. aeruginosa) accounted for 37% of all
bacterial isolates.
We performed a univariate analysis comparing graft function
impairment with the presence of AGP due to resistant strains
(ESBL-producing Enterobacteriaceae and MDR P. aeruginosa).
Patients with AGP caused by a resistant strain had impairment
in graft function more frequently than patients with AGP causedClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeby a non-resistant strain, although the difference did not reach
statistical signiﬁcance (53% vs. 36%, p 0.07). Patients with AGP
and AU UTI had kidney graft function impairment by 1 year
after transplantation more frequently than those without UTI
or those with AB (p 0.004). One-year post-transplantation graft
loss was more frequent in patients with AGP than in all other
patient groups (p 0.014) (Table 2).ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1104.e1–1104.e8
TABLE 2. One-year impaired kidney graft function and graft
survival by presence and type of urinary tract infection (UTI)
Impaired kidney graft
function Graft loss
Yes, n (%) No, n (%) Yes, n (%) No, n (%)
No UTI 105 (23) 350 (77) 18 (4) 437 (96)
Asymptomatic bacteriuria 59 (26) 169 (74) 3 (1) 225 (99)
Acute uncomplicated UTI 14 (24) 44 (76) 3 (5) 55 (95)
Acute graft pyelonephritis 47 (37) 79 (63) 14 (11) 112 (89)
Patients with acute graft pyelonephritis more frequently had impaired kidney graft
function (p 0.004) and graft loss (p 0.014) than patients without UTI or with
asymptomatic bacteriuria. Impaired kidney graft function was also more frequent
among patients with acute uncomplicated UTI than in the other groups (p 0.004).
1104.e5 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIIndependent risk factors for kidney graft function impairment
at 1 year were surgical re-intervention (OR 1.4; 95% CI 1.0–2.0)
and the development of at least one episode of AGP (OR 2; 95%
CI 1.3-3.2) (Table 3). Neither AB norAUUTIwas associated with
graft function impairment in multivariate analysis. Patients aged
>60 years had impaired kidney graft function more frequently,
and the difference almost reached statistical signiﬁcance. Recur-
rent UTI did not signiﬁcantly impair a patient’s kidney graft
function as compared with single UTI episodes (p 0.085). More-
over, it did not affect graft survival (log-rank test, 0.27).
Fig. 3 shows the Kaplan–Meier survival curves for graft
survival by UTI category. There were no differences in 1-year
graft survival between patients without UTI, with AB, and
with AU UTI. However, patients with AGP had worse graft
survival (log-rank test, <0.001). Graft loss during the ﬁrst year
after transplantation resulted from graft vascular complications
(53%), chronic allograft rejection (19%), infection (9%), and
multifactorial causes (6%). Of the patients who lost their graft,
13% died with a functional graft. During the follow-up period,
chronic allograft rejection was the leading reason for graft loss
(53%), followed by graft vascular complications (30%), in-
fections of any source and aetiology (9%), and multifactorial
causes (8%).TABLE 3. Logistic regression model of variables evaluated as predi
transplant recipients
Variable n Impaired kidney graft function, n (%
Gendera
Male 520 131 (27.6)
Female 347 94 (30.7)
Agea
60 years 254 72 (33.5)
<60 years 613 153 (27)
Acute graft pyelonephritis
Yes 126 47 (43.5)
No 741 178 (26.4)
Surgical re-intervention
Yes 256 75 (35.2)
No 611 150 (26.4)
aVariable age and gender were included in the ﬁnal regression model due to theoretical rea
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectDiscussionIn this large cohort of adult kidney transplant recipients, we
found that presenting with one or more episodes of AGP was
signiﬁcantly associated with impaired kidney graft function and
graft loss 1 year after transplantation. However, lower UTI had
no impact on long-term graft function or survival.
Other investigators have assessed the impact of UTIs on
patient and graft outcome. Giral et al. found that early AGP
(within 3 months of transplantation) was signiﬁcantly detri-
mental to graft outcome, and another French study found that,
as compared with uncomplicated UTI, patients with AGP
showed an increase in serum creatinine and a decrease in
creatinine clearance 1 year after transplantation [2,6]. Never-
theless, other researchers have failed to ﬁnd a relationship
between UTI and renal graft function [8,19,20]. Moreover, in
contrast to our ﬁndings, one study that analysed a large cohort
of kidney transplant recipients in the USA found that late UTI
was signiﬁcantly associated with an increased risk of subsequent
death [21]. It is important to point out that some of these
studies did not use standardized deﬁnitions of UTI, and that
they did not differentiate between early and late infection
[9,10,22], making it difﬁcult to generalize their conclusions in
the absence of randomized controlled trials.
Several hypotheses could explain the negative impact of UTI
on graft function. First, bacterial infection could activate the
immune system, thereby leading to acute or chronic rejection
and, consequently, deteriorating graft function. In this regard,
some authors have suggested that AGP can result in interstitial
scars that subsequently reduce the functional nephron mass and
cause renal function impairment [23]. Dupont et al. found
kidney scarring by the use of single-photon emission computed
tomography imaging of patients with late recurrent UTI [24],
which is consistent with our ﬁndings that patients with AGP
presented with acute allograft rejection more frequently, withctive factors of 1-year impaired kidney graft function in kidney
)
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
1.1 (0.8–1.6) 0.3 — —
1.3 (0.9–2) 0.07 1 (0.9–1.1) 0.5
2.2 (1.4–3.2) <0.001 2 (1.3–3.2) 0.001
1.5 (1.1–2.1) 0.01 1.4 (1–2) 0.04
sons.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1104.e1–1104.e8
FIG. 3. Kaplan–Meier survival graph of the percentage of patients free of graft loss or death according to the occurrence and type of urinary tract
infection (UTI) after kidney transplantation. The percentage of patients free of graft loss or death was lower among patients with acute graft py-
elonephritis (AGP) (89%) than among those with acute uncomplicated (AU) UTI (95%), asymptomatic bacteriuria (AB) (99%), or no UTI (96%) (log-
rank test, p <0.001).
CMI Bodro et al. Impact of acute pyelonephritis on graft survival 1104.e6the difference almost reaching statistical signiﬁcance [22,23,25].
However, it could be hypothesized that the occurrence of AGP
could be a reason for decreasing immunosuppressive treat-
ment, favouring graft rejection. Moreover, chronic allograft
rejection was the leading cause of graft loss during the follow-
up period, and the third most common cause in the ﬁrst year.
Elevated urinary cytokines are found in kidney transplant re-
cipients with AB, which may reﬂect an impaired immune
response to bacterial infection and occult inﬂammation in the
urinary tract [26]. Nevertheless, as Kamath et al. suggested, the
process of infection and immune activation can be bidirectional,
given their ﬁnding that 41% and 28% of patients experienced
acute rejection episodes before and after an episode of AGP,
respectively [8].
Another important ﬁnding of our study was the high per-
centage of drug-resistant strains, especially of ESBL-producing
Enterobacteriaceae. These rates are consistent with recent
publications that reported an increase of the incidence of in-
fections caused by MDR pathogens in solid organ transplant
recipients [27,28]. Interestingly, some studies have found that
infections caused by resistant strains result in worse outcomes
than infections caused by their antibiotic-susceptible counter-
parts [28]. Thus, we think that our results may have been
inﬂuenced by this high percentage of infections caused by MDR
organisms. Patients with AGP caused by resistant strains hadClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeworse graft function than those in the other groups, with the
difference almost reaching statistical signiﬁcance. In vitro studies
have found speciﬁc virulence factors, such as ﬁmbriae in E. coli
strains, which may also contribute to a deterioration in graft
function in kidney transplant recipients [29]. Therefore, further
microbiological studies are needed to clarify the virulence fac-
tors present in these resistant isolates that contribute to de-
teriorations in graft function.
Our analysis found that deceased donors, concomitant
invasive fungal and CMV infection, re-intervention, neph-
rostomy and post-transplantion haemodialysis were more
frequent among patients with AGP. Cadaveric donors, re-
intervention, nephrostomy and post-transplantion haemodial-
ysis will undoubtedly be recognized as classic risk factors for
infection risk, owing to the urinary tract manipulation, which is
known to favour infection. However, the relationship of viral
and fungal infections with AGP is less well known. Some re-
searchers have speculated that a UTI could reactivate CMV by
increasing the level of tumour necrosis factor in response to
bacterial invasion [30], a phenomenon that has been observed
in some studies in which CMV became activated during infec-
tion or intercurrent illness [6,8,19,28]. Moreover, it is known
that CMV has immunomodulatory effects that could facilitate
infection.ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1104.e1–1104.e8
1104.e7 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIImportantly, UTI occurs early after transplantation.
Accordingly, patients with AGP are more manipulated in the
ﬁrst months after transplantation, more frequently requiring a
re-intervention, nephrostomy, and haemodialysis, and needing
double-J stent catheterization for longer than the other groups.
Thereby, shortening or avoiding urethral and double-J cathe-
terization is mandatory to reduce the incidence of UTI and
consequently to reduce graft injury.
In conclusion, UTIs were frequent in kidney transplant re-
cipients and usually occurred early in the post-transplantation
period. AGP was signiﬁcantly associated with impaired kidney
graft function and 1-year post-transplantation graft loss. How-
ever, the present study has two major limitations. First, it was
performed in a single centre, so the results may be inﬂuenced
by local epidemiological variables, limiting their applicability to
other settings. Second, owing to the retrospective design, some
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